CHAEBOL WATCH · A file on chaebol leverage points · Built on finalized rulings and official records
The Chaebol Leverage File Seven real cases of the convict-then-pardon pattern
Samsung Biologics’ ₩4.5T accounting fraud, SK’s Chey Tae-won embezzlement, Lotte’s Shin Dong-bin bribery, Hanjin’s Nut Rage, Lee Myung-bak’s ₩11B DAS case, Kakao’s SM stock manipulation, CJ’s Lee Jay-hyun pardoned twice — court records the Korean press quietly moved past.
※ Convictions, arrests, and pardons are based on official records. Ongoing trials are marked as of their reference date.
₩4.5T
Samsung Biologics fraud scale
₩1.3T
SK Chey Tae-won asset division
17 years
Lee Myung-bak’s finalized sentence
₩240B
Kakao stock manipulation scale
1 / 8
SAMSUNG BIOLOGICS · ₩4.5T accounting fraud · Tied to Lee Jae-yong’s succession
Samsung Biologics manipulated ₩4.5 trillion in accounting — to inflate the merger ratio behind Lee Jae-yong’s succession
In 2015, Samsung Biologics changed how it accounted for its subsidiary Samsung Bioepis, booking a ₩4.5 trillion valuation gain in a single stroke. The change happened right before the Samsung C&T–Cheil Industries merger, inflating Cheil Industries’ valuation and producing a merger ratio favorable to Lee Jae-yong.
⚖ Financial Services Commission ruling — intentional accounting fraud confirmed (2018) · CEO referred to prosecutors
How the accounting trick worked
›Until 2015, Samsung Bioepis (a Samsung Biologics subsidiary) was booked as a consolidated subsidiary — recorded at acquisition cost (about ₩600 billion).
›In 2015, Samsung Biologics abruptly reclassified Bioepis as an "affiliate" instead. Under that classification, it had to be revalued at fair (market) value.
›After reclassification, Bioepis’ fair value was assessed at roughly ₩5 trillion. The jump from ₩600 billion to ₩5 trillion on the books produced a sudden ₩4.4 trillion valuation gain.
›That ₩4.5 trillion gain flipped Samsung Biologics from a loss-making company to a profitable one on paper — and its valuation spiked.
›Because Samsung Biologics was Cheil Industries’ core asset, the inflated valuation raised Cheil Industries’ value, which set the Samsung C&T–Cheil Industries merger ratio in Cheil’s favor.
The direct link to Lee Jae-yong’s succession
›Higher Cheil Industries valuation → a merger ratio favorable to Cheil → a larger stake in the merged Samsung C&T for Lee Jae-yong, who held 23.2% of Cheil.
›Without the accounting fraud inflating Cheil’s value, the merger ratio would likely have been set differently — and Lee Jae-yong’s succession stake would have been smaller.
›The Financial Supervisory Service’s 2018 finding: the accounting treatment "was a deliberate manipulation for management purposes rather than economic substance" — ruled intentional fraud.
›Samsung Biologics CEO Kim Tae-han and other executives were referred to prosecutors. Indictments and trials followed.
›The case triggered a long legal fight running through the Securities and Futures Commission, the Financial Services Commission, prosecutors, and the courts.
Why the US SEC took notice
›Samsung Biologics trades on the Korea Exchange (KRX), but discussion of a US ADR listing and interest from global biotech investors drew outside attention.
›Analyses under both US GAAP and IFRS found problems with Samsung Biologics’ accounting treatment.
›When the fraud came to light, shares held by global institutional investors fell sharply; some foreign investors reportedly weighed damages claims.
›International transparency organizations cited the case as emblematic of distrust in Korean corporate accounting — one contributor to the "Korea discount" in equity valuations.
The trial as of 2024
›Former Samsung Biologics CEO Kim Tae-han: 2-year suspended sentence at first instance. Prosecutors appealed.
›Former Samsung C&T CEO Choi Chi-hoon and other merger-related figures face separate, ongoing trials.
›For Lee Jae-yong himself, the central question is whether he "conspired" in the scheme — prosecutors have struggled to produce direct evidence of his personal instructions.
›The case was still active as of 2024; a final ruling is expected to take several more years.
›Key point: Lee Jae-yong received a pardon, but the investigation and trial over this accounting-fraud case are separate proceedings — whether the pardon applies here requires separate legal review.
SOURCES & DISCLAIMER
This page draws on Korean court rulings, administrative sanctions, and corporate disclosures, alongside international arbitration records and major foreign-press coverage. Finalized court rulings, administrative findings, ongoing trials, and AMS’s own structural interpretation are not the same standard of evidence — read each case’s status and reference date accordingly.
US Courts & Regulators
U.S. Securities and Exchange Commission (SEC) — disclosures related to the Samsung Biologics accounting review
U.S. Department of Justice (DOJ) — Hyundai/Kia Theta II engine criminal settlement record ($210M, 2021)
U.S. District Court, N.D. California — Samsung v. Apple patent jury verdict ($539M)
U.S. District Court, N.D. California — DRAM price-fixing $485M settlement record
U.S. District Court, M.D. Alabama — Hyundai Alabama child-labor $19.5M settlement (2023)
International Arbitration & Foreign Press
Permanent Court of Arbitration (PCA) — Elliott v. Republic of Korea, PCA Case No. 2018-51 (award issued 2022.06)
International Centre for Settlement of Investment Disputes (ICSID) — related investment arbitration records
The Wall Street Journal — ongoing coverage of the Samsung succession merger and Lee Jae-yong’s trial (2016–2023)
Financial Times — analysis series on Samsung governance and the Elliott dispute
Bloomberg — real-time coverage of the Lotte, SK, and Kakao cases
Reuters — international coverage of Hanjin’s Nut Rage incident (2014)
Official Korean Records
Supreme Court ruling — Lee Myung-bak, 17-year sentence finalized (2020.10.29, Supreme Court Case No. 2020Do5765)
Seoul High Court — Roh Soh-yeong / Chey Tae-won divorce asset division, ₩1.3808T (2023.05.26)
Seoul Southern District Court — arrest warrant issued for Kim Beom-su (2024.07.23)
Korean Air disclosure — Asiana Airlines merger review filing materials (2024)
Academic & Think Tanks
Korea Economic Institute of America (KEI) — reports on chaebol governance
Transparency International — annual Corruption Perceptions Index reports on Korea
Human Rights Watch — investigation into child labor in Hyundai’s US supply chain (2022)
Corporate Governance Asia — governance ratings for Samsung, SK, and Lotte
※ This page was not created to attack or defame any specific company or individual. It compiles publicly available rulings, administrative actions, and foreign-press reporting as a matter of the public’s right to know. Ongoing cases are marked with their reference period (2024–2025), and unconfirmed findings are separately noted.